Loading stock data…
CBUS
$1.45+0.05 (+3.57%)
Market ClosedLast close May 1
Cibus, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cibus, Inc. in the Healthcare sector is trading at $1.45. The stock is currently near its 52-week low of $1.09, remaining 19.9% below its 200-day moving average. Technical signals show neutral RSI of 50 and bullish MACD crossover, explaining why CBUS maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 50) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.45
Potential Upside
5%
Whystock Fair Value$1.52
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$120.58M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.93
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-582.18%
Volume
Today's trading volume
324,603
Recent News
Cibus, Inc. Q4 2025 Earnings Call Summary
Moby summary of Cibus, Inc.'s Q4 2025 earnings call
Cibus Q4 Earnings Call Highlights
Cibus (NASDAQ:CBUS) used its fourth quarter 2025 results call to highlight a year the company described as a commercial and regulatory inflection point for gene editing in agriculture, citing expanding customer traction in rice, early revenue in sustainable ingredients, and what management called “w
Cibus Inc (CBUS) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
Cibus Inc (CBUS) showcases significant technological progress and strategic partnerships, despite reporting increased net losses and financial constraints.
Cibus (CBUS) Q4 2025 Earnings Call Transcript
By any measure, 2025 was a landmark year for Cibus, Inc., not because of any single headline, but because of a convergence of key themes that are shaping the trajectory of the gene editing industry. Gene editing is no longer an experiment. What makes this current moment particularly exciting is the intersection of our technology readiness and a change in how we believe seed companies are thinking about gene editing.
Cibus (CBUS) Reports Q4 Loss, Lags Revenue Estimates
Cibus (CBUS) delivered earnings and revenue surprises of +2.33% and -27.85%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?